AI Article Synopsis
- Peritoneal dialysis-associated peritonitis (PDAP) presents major challenges for managing PD patients, and the role of total bilirubin in predicting treatment outcomes is not well understood.
- A study involving 243 PDAP patients found a non-linear relationship between total bilirubin levels and treatment failure risk, showing that low levels (below 8.24 µmol/L) offer protection, whereas higher levels increase failure risk.
- The findings highlight the complex role of total bilirubin in PDAP prognosis, suggesting the need for more comprehensive studies to confirm these results and explore bilirubin's mechanisms for potential therapeutic applications.
Article Abstract
Peritoneal dialysis-associated peritonitis (PDAP) poses significant challenges in peritoneal dialysis (PD) patient management and outcomes. Total bilirubin has gained attention due to its antioxidant and immunomodulatory properties. However, its relationship with PDAP prognosis remains underexplored. We conducted a retrospective single-center study involving 243 PDAP patients stratified into tertile-based groups according to total bilirubin levels. The association between total bilirubin levels and treatment failure risk was investigated through statistical analyses and restricted cubic spline curve analysis. Our analysis revealed a non-linear correlation between total bilirubin levels and PDAP treatment failure risk. At total bilirubin levels below 8.24 µmol/L, a protective effect was observed, while levels exceeding this threshold heightened the risk of treatment failure. This study unveils a dual role of total bilirubin in PDAP prognosis. Below a certain threshold, it confers protection, while higher levels exacerbate the risk of treatment failure. These findings emphasize the need for further investigation in larger, multicenter prospective studies to validate and elucidate the mechanisms behind bilirubin's impact on PDAP, potentially guiding the development of targeted therapeutic strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607946 | PMC |
| http://dx.doi.org/10.3390/medicina59101837 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sequential Targeting Chondroitin Sulfate-Bilirubin Nanomedicine Attenuates Osteoarthritis via Reprogramming Lipid Metabolism in M1 Macrophages.
Adv Sci (Weinh)
January 2025
Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
The infiltration and excessive polarization of M1 macrophages contribute to the induction and persistence of low-grade inflammation in joint-related degenerative diseases such as osteoarthritis (OA). The lipid metabolism dysregulation promotes M1 macrophage polarization by coordinating the compensatory pathways of the inflammatory and oxidative stress responses. Here, a self-assembling, licofelone-loaded nanoparticle (termed LCF-CSBN), comprising chondroitin sulfate and bilirubin joined by an ethylenediamine linker, is developed to selectively reprogram lipid metabolism in macrophage activation.
View Article and Find Full Text PDFPrognostic Value of Serum Bilirubin in Aneurysmal Subarachnoid Hemorrhage Patients.
Curr Neurovasc Res
January 2025
Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Background: Bilirubin plays a crucial role in the pathophysiological processes of strokes. However, the relationship between serum bilirubin levels and the prognosis of aneurysmal subarachnoid hemorrhage (aSAH) remains unexplored. This study aims to investigate the association between serum bilirubin levels and the mortality rate of aSAH patients.
View Article and Find Full Text PDFTherapeutic Potential of Hongjam in A Diethylnitrosamine and Thioacetamide-induced Hepatocellular Carcinoma Mouse Model.
J Cancer Prev
December 2024
College of Pharmacy and Institute of Pharmaceutical Sciences, CHA University, Seongnam, Korea.
Hepatocellular carcinoma (HCC) is the most common and lethal type of primary liver cancer, frequently arising from chronic liver injury and inflammation. Despite treatment advancements, HCC prognosis remains poor, emphasizing the need for effective preventive and therapeutic strategies. This study investigates the hepatoprotective and anti-tumor effects of Hongjam, a steamed freeze-dried silkworm powder, in a diethylnitrosamine (DEN) and thioacetamide (TAA)-induced HCC mouse model.
View Article and Find Full Text PDFPrediction of urinary tract infection using machine learning methods: a study for finding the most-informative variables.
BMC Med Inform Decis Mak
January 2025
Department of Pediatrics, School of Medicine, Ekbatan Hospital, Hamadan University of Medical Sciences, Hamadan, Iran.
Background: Urinary tract infection (UTI) is a frequent health-threatening condition. Early reliable diagnosis of UTI helps to prevent misuse or overuse of antibiotics and hence prevent antibiotic resistance. The gold standard for UTI diagnosis is urine culture which is a time-consuming and also an error prone method.
View Article and Find Full Text PDFA real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib.
Sci Rep
January 2025
Department of Hepatobiliary and Pancreatic Surgery, Taihe Hospital, Affiliated Hospital of Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Pembrolizumab plus Lenvatinib is regarded as a significant treatment option for advanced unresectable hepatocellular carcinoma (HCC). This study aims to meticulously monitor and identify adverse events (AEs) related to this combined therapy, enhance patient safety, and offer evidence-based recommendations for the appropriate use of these drugs. We gathered adverse drug reactions (ADRs)-related data from the FAERS database for HCC patients who received Pembrolizumab, both alone and in combination with Lenvatinib from the first quarter of 2014 to the fourth quarter of 2023.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!